Trasylol Side Effects Lawsuits | Side Effects: Kidney Failure, Kidney Damage,...
CLICK HERE TO DOWNLOAD OUR TRASYLOL INFORMATION PACKAGE Trasylol Side Effects Could Result In Kidney Failure Lawsuits Trasylol | Lawsuits, Lawyers | Side Effects: Kidney Failure, Kidney Damage,...
View ArticleClotting drug increases kidney risk, study finds
A drug commonly used to prevent excessive bleeding in heart-surgery patients greatly increased the risk of kidney failure, a new international study found.The drug aprotinin marketed under the brand...
View ArticleMultiple Risks of Surgery Drug Seen
A drug widely used during heart surgery to control bleeding doubles the risk of kidney damage, forcing an estimated 10,000 patients onto dialysis each year, according to a study from a group calling...
View ArticleStudy: Cardiac Drug Doubles Risk of Kidney Failure
Aprotinin. a drug approved by the FDA, marketed internationally for the last 13 years, and given to an estimated one million surgery patients to limit bleeding has now been proven to double a patient's...
View ArticleHeart-surgery drug risky, researchers find
A drug widely used during heart surgery to control bleeding doubles the risk of kidney damage, forcing an estimated 10,000 patients onto dialysis each year, according to a new study from a group that...
View ArticleParker & Waichman, LLP Evaluating Trasylol Claims After Study Links...
Parker & Waichman, LLP (www.yourlawyer.com) announces that, in addition to numerous inquiries from potential clients, it has been retained in a case involving the use of Trasylol and is actively...
View ArticleFDA Public Health Advisory Aprotinin Injection (marketed as Trasylol)
On January 26, 2006, The New England Journal of Medicine (NEJM) published an article by Mangano et al. reporting an association of Trasylol (aprotinin injection) with serious renal toxicity and...
View ArticleFDA Issues Public Health Advisory for Trasylol
The Food and Drug Administration today issued a Public Health Advisory alerting doctors who perform heart bypass surgery, and their patients, that Trasyolol (aprotinin injection), a drug used to...
View ArticleFDA Urges Limited Use of Trasylol Pending Review of Data Showing Increased...
The Food and Drug Administration (FDA) has issued an advisory to doctors urging them to limit the use of Bayer AG’s heart-surgery medication, Trasylol, pending an agency review of research that shows...
View ArticleFDA Statement Regarding New Trasylol Data
Since January, 2006, the Food and Drug Administration (FDA) has been conducting a safety review of Trasylol (aprotinin injection). The review was triggered by the results of two published research...
View ArticleBayer Suspends 2 Over Trasylol Data
Bayer AG said Friday it suspended two employees involved in the decision to withhold data from federal health officials showing the company's drug Trasylol can cause deadly side effects. Bayer,...
View ArticleFDA Approves New Warning for Bayer Drug
Government health officials said Friday they have approved a new label for Bayer's Trasylol that highlights the possible risk of kidney damage associated with taking the drug. More than 600,000 people...
View ArticleFDA strengthens safety warning on aprotinin label
The FDA has strengthened the label safety warning for the antifibrinolytic drug aprotinin (Trasylol, Bayer), emphasizing the importance of limiting use of the agent to patients undergoing CABG. The...
View ArticleBayer’s Heart-Surgery Drug Increases Risk of Death
Bayer’s controversial heart-surgery drug aprotinin, marketed as Trasylol, is under fire yet again thanks to a new study that found that the drug carries with it an increased risk of long-term...
View ArticleAprotinin, drug used in cardiac surgery, heightens death risk: study
Researchers have found that as drug used to staunch blood loss in patients undergoing cardiac surgery can raise the risk of death over the medium term. According to a new study published in the...
View ArticleInternational study: Five-year death rate higher in heart surgery patients...
Patients who are given a widely used drug to prevent excessive bleeding during heart surgery are at increased risk of dying within five years following their operations, medical researchers have found...
View ArticleCostly bypass medication may raise death risk later
An expensive drug given to coronary artery bypass surgery patients to prevent excessive bleeding is linked to an increased risk of dying as long as five years after the operation, researchers report...
View ArticleHeart surgery drug linked to death risk
A drug widely used to prevent excessive bleeding during heart surgery appears to raise the risk of dying in the five years afterward by nearly 50 percent, an international study found. The researchers...
View ArticleTrasylol Kidney, Death Risks to Be Investigated by FDA Advisory Panel
Trasylol, a drug used to prevent bleeding during heart bypass surgeries that has been linked to kidney failure, will face the scrutiny of a Food & Drug Administration (FDA) advisory panel for the...
View ArticleTrasylol Should Remain on Market Says FDA Panel, Despite Risk of Kidney...
Drug Safety reviewers say Trasylol should remain on the market, despite being linked to an increased risk death. Yesterday, a Food & Drug Administration (FDA) advisory panel voted 16-1 to...
View Article
